Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS006 vs Rituximab plus CHOP in first-line CD20-positive DLBCL
CTR20180855Phase 3Completed
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Jul 2018
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of hlx01 in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd.. Started Jul 2018; status: completed.
02
Drugs
hlx01
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20180855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180855.